R&D AMR and vaccines: Can universal coverage avert a post-antibi... Antimicrobial resistance (AMR) is a growing global health crisis.
R&D Treating the chronic diseases GLP-1s miss, with Laurent Auda... Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.
R&D Changing Faces: Pharma and biotech, January 2026 The new year brought a slew of new faces in the pharma and biotech world, especially in the top jobs, with a number of CEO changes at biotech firms.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
R&D Strategies for creating an ecosystem to support early-stage ... Learn how to foster growth for early-stage biotech companies through innovative ecosystem strategies and valuable CDMO collaborations
R&D Navigating the new ICH E6 (R3): Key changes for sponsors These new regulations for running clinical trials in the UK will be a legal requirement from 28th April 2026.
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
